These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 5776992)

  • 1. Further observations on the cardiovascular effects of ST 155 (Catapres).
    Nayler WG; Price JM; Stone J; Lowe TE
    J Pharmacol Exp Ther; 1969 Apr; 166(2):364-73. PubMed ID: 5776992
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of the hypotensive drug ST 155 (Catapres) on the heart and peripheral circulation.
    Nayler WG; Price JM; Swann JB; McInnes I; Race D; Lowe TE
    J Pharmacol Exp Ther; 1968 Nov; 164(1):45-59. PubMed ID: 5722106
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues.
    Van Nueten JM; Janssen PA
    Arch Int Pharmacodyn Ther; 1973 Jul; 204(1):37-55. PubMed ID: 4746630
    [No Abstract]   [Full Text] [Related]  

  • 4. An effect of ST 155 (clonidine), 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride, Catapres on relationship between blood pressure and heart rate in dogs.
    Nayler WG; Stone J
    Eur J Pharmacol; 1970 May; 10(2):161-7. PubMed ID: 5446372
    [No Abstract]   [Full Text] [Related]  

  • 5. Myocardial effects of imidazole.
    Knope R; Moe GK; Saunders J; Tuttle R
    J Pharmacol Exp Ther; 1973 Apr; 185(1):29-34. PubMed ID: 4693184
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro myocardial effects of 4-(3,4-dimethoxybenzyl)-2-imidazolidinone (Ro 7-2956).
    Kline RL; Buckley JP
    J Pharmacol Exp Ther; 1972 Sep; 182(3):399-408. PubMed ID: 4403432
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac slowing effects of clonidine (ST-155) in dogs.
    Scriabine A; Stavorski J; Wenger HC; Torchiana ML; Stone CA
    J Pharmacol Exp Ther; 1970 Feb; 171(2):256-64. PubMed ID: 5272380
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemodynamic effects of 4-(3,4-dimethoxybenzyl)-2-imidazolidinone (Ro 7-2956): a nonadrenergic myocardial stimulant.
    Osborne MW; Wenger JJ; Moe RA
    J Pharmacol Exp Ther; 1971 Jan; 176(1):174-83. PubMed ID: 4398214
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP).
    Cheng HC; Long JP; Barfknecht CF; Nichols DE
    J Pharmacol Exp Ther; 1973 Aug; 186(2):345-54. PubMed ID: 4719787
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cardiovascular effects of capsaicin. Experiment using dogs with a chronically implanted radio-telemeter for blood pressure determination].
    Ueno A
    Nihon Yakurigaku Zasshi; 1971 Nov; 67(6):572-9. PubMed ID: 5168945
    [No Abstract]   [Full Text] [Related]  

  • 11. An involvement of St 155 [2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride, catapres] in cholinergic mechanisms.
    Robson RD; Kaplan HR
    Eur J Pharmacol; 1969 Mar; 5(4):328-37. PubMed ID: 4389147
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of disulfiram on the cardiovascular responses to ethanol in dogs and guinea pigs.
    Nakano J; Holloway JE; Schackford JS
    Toxicol Appl Pharmacol; 1969 May; 14(3):439-46. PubMed ID: 5787513
    [No Abstract]   [Full Text] [Related]  

  • 13. Proceedings: Review of the cardiovascular pharmacology of perhexiline.
    Hudak WJ; Lewis RE; Lucas RW; Kuhn WL
    Postgrad Med J; 1973 Apr; 49():Suppl 3:16-25. PubMed ID: 4202743
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular and metabolic effects of cyclic adenosine 3', 5'-monophosphate in unanesthetized dogs.
    Levine RA; Vogel JA
    J Pharmacol Exp Ther; 1966 Feb; 151(2):262-72. PubMed ID: 4379816
    [No Abstract]   [Full Text] [Related]  

  • 15. Some observations on the pharmacological effects of salbutamol, with particular reference to the cardiovascular system.
    Nayler WG
    Postgrad Med J; 1971 Mar; 47():Suppl:16-21. PubMed ID: 5572512
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the cardiovascular effects of synthetic vasopressin.
    Nakano J
    J Pharmacol Exp Ther; 1967 Jul; 157(1):19-31. PubMed ID: 6029485
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular pharmacology of perhexiline.
    Hudak WJ; Lewis RE; Kuhn WL
    J Pharmacol Exp Ther; 1970 Jun; 173(2):371-82. PubMed ID: 4988496
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of drugs affecting cyclic AMP levels on methadone induced potentiation of adrenaline effects.
    Huidobro F; Contreras E; Tamayo L
    Arch Int Pharmacodyn Ther; 1972; 198(1):29-35. PubMed ID: 4340827
    [No Abstract]   [Full Text] [Related]  

  • 20. Cerebral and coronary vascular effects of a symmetrical N,N'-disubstituted hexahydrodiazepine.
    Buyniski JP; Losada M; Bierwagen ME; Gardier RW
    J Pharmacol Exp Ther; 1972 Jun; 181(3):522-8. PubMed ID: 5033017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.